Table I. Hormone replacement therapy (HRT) regimes, doses and dose schedules used by study subjects
| Estrogen |
Progestogen/CPA |
No. of sequential HRT users (n = 24) |
No. of continuous combined HRT users (n = 10) |
|
| Estradiol 50 µg |
NET 1 mg |
2 |
|
| Estradiol 50 µg |
NET 170 µg |
1 |
2 |
| Estradiol 50 µg |
NET 170 µg and dydrogesterone 20 mg |
|
1 |
| Estradiol 50 µg |
No progestogen used for 3 months |
1 |
|
| Estradiol 80 µg |
Duphaston 10 mg |
1 |
|
| Estradiol 80 µg |
Duphaston 10 mg and MPA 2.5 mg |
|
1 |
| Estradiol valerate 1 mg |
NET 1 mg |
1 |
|
| Estradiol valerate 2 mg |
NET 1 mg |
3 |
|
| Estradiol valerate 2 mg |
LNG 75 µg |
1 |
|
| Estradiol valerate 2 mg |
MPA 20 mg |
1 |
|
| Estradiol 1 mg |
NET 1 mg |
1 |
|
| Estradiol 2 mg |
NET 1 mg |
2 |
1 |
| Estradiol 4 mg |
NET 1 mg |
1 |
|
| Estradiol 4 mg |
NET 2 mg |
1 |
|
| Estradiol 50µg |
NET 250 µg |
2 |
|
| Conjugated estrogen 0.625 mg |
MPA 5 mg |
|
2 |
| Conjugated estrogen 0.625 mg |
MPA 2.5 mg |
3 |
1 |
| Conjugated estrogens 1.25 mg |
MPA 5 mg |
1 |
1 |
| Conjugated estrogens 1.25 mg |
norgestrel 150 µg |
|
1 |
| Conjugated estrogens 1.25 mg |
CPA 25 mg |
2 |
|
| Total |
|
24 |
10 |
| |
CPA = cyproterone acetate; NET = norethisterone; LNG = levonorgestrel; MPA = medroxyprogesterone acetate.
